China Universal Asset Management Co. Ltd. Acquires 3,696 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

China Universal Asset Management Co. Ltd. lifted its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 64.7% in the 3rd quarter, HoldingsChannel reports. The fund owned 9,409 shares of the biopharmaceutical company’s stock after purchasing an additional 3,696 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Theravance Biopharma were worth $76,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Ballentine Partners LLC bought a new stake in Theravance Biopharma during the 3rd quarter worth approximately $104,000. Hsbc Holdings PLC bought a new stake in Theravance Biopharma during the second quarter worth $108,000. XTX Topco Ltd purchased a new stake in Theravance Biopharma in the 2nd quarter valued at $129,000. State Board of Administration of Florida Retirement System boosted its holdings in Theravance Biopharma by 28.2% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 4,990 shares during the last quarter. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Theravance Biopharma in the 2nd quarter worth $286,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on TBPH. Leerink Partners lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $15.00 to $10.00 in a research report on Tuesday, August 6th. Leerink Partnrs downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. StockNews.com lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. TD Cowen reduced their price objective on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a research note on Monday, September 16th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $13.75.

Theravance Biopharma Price Performance

NASDAQ:TBPH opened at $8.24 on Friday. The company has a market capitalization of $400.74 million, a P/E ratio of -9.58 and a beta of 0.25. The business has a fifty day simple moving average of $8.25 and a two-hundred day simple moving average of $8.73. Theravance Biopharma, Inc. has a 1 year low of $7.44 and a 1 year high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.25). The firm had revenue of $14.26 million during the quarter, compared to analysts’ expectations of $15.81 million. Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. During the same period last year, the business posted ($0.28) EPS. As a group, analysts anticipate that Theravance Biopharma, Inc. will post -1.04 earnings per share for the current year.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, major shareholder Eli Samaha purchased 999,800 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were bought at an average cost of $7.80 per share, for a total transaction of $7,798,440.00. Following the purchase, the insider now owns 9,511,150 shares of the company’s stock, valued at $74,186,970. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 6.90% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.